Zhuravleva M V, Davydovskaya M V, Luchinina E V, Shelekhova T V, Kurguzova D O, Serebrova S Yu
Scientific Center for Examination of Medical Devices of the Ministry of Health of Russia, Moscow, Russia.
Sechenov First Moscow State Medical University of the Ministry of Health of Russia, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(8):148-153. doi: 10.17116/jnevro2020120081148.
This review aims at describing clinical benefits and characteristics of the main highly effective disease modifying drugs (DMD) for multiple sclerosis (MS): alemtuzumab, cladribine tablets, ocrelizumab, natalizumab, fingolimod based on the efficacy and safety. The authors highlight that all MS DMDs have certain benefits and features that shall be considered in prescribing pharmacotherapy. Cladribine in tablets are comparable by the efficacy to other modern highly effective second-line drugs, have a high level of evidence and a favorable safety profile, as well as the most preferred benefit/risk ratio among other MS DMDs indicated for the treatment of highly active MS, which offers an advantage to the drug. The use of cladribine in tablets will contribute to further study of the efficacy and safety of this highly efficient drug for MS treatment.
本综述旨在基于疗效和安全性，描述用于治疗多发性硬化症（MS）的主要高效疾病修正药物（DMD）：阿仑单抗、克拉屈滨片、奥瑞珠单抗、那他珠单抗、芬戈莫德的临床益处和特点。作者强调，所有MS DMD都有一定的益处和特征，在开药物治疗处方时应予以考虑。克拉屈滨片在疗效上与其他现代高效二线药物相当，有高水平的证据和良好的安全性，并且在用于治疗高度活动性MS的其他MS DMD中具有最有利的获益/风险比，这为该药物提供了优势。使用克拉屈滨片将有助于进一步研究这种高效药物治疗MS的疗效和安全性。
